QTY Code Cytokine Receptors (Six Variants)
Inflammatory & Immune Conditions (Research Platform)
Pre-clinicalActive Research & IP Development
Key Facts
Indication
Inflammatory & Immune Conditions (Research Platform)
Phase
Pre-clinical
Status
Active Research & IP Development
Company
About Avalon GloboCare
Founded in 2016 and uplisted to Nasdaq in 2018, Avalon GloboCare is advancing precision diagnostics through its proprietary platforms. The company's KetoAir™ breathalyzer is an FDA-registered Class I medical device for ketosis monitoring, while its QTY code platform, developed with MIT, is focused on designing water-soluble cytokine receptors. Avalon operates with approximately 60 full-time employees and is actively expanding its intellectual property portfolio and strategic partnerships.
View full company profile